← Eichor
Condition: Non Squamous Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Non Squamous

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib
Phase 2 · 2 location(s) · Jair Bar, M.D., Ph.D. · NCT06206850Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05837767A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 47 location(s) · Bristol-Myers Squibb · NCT04895709A Multicenter Cancer Biospecimen Collection Study
Phase N/A · 1 location(s) · Cofactor Genomics, Inc. · NCT04510129A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1 · 1 location(s) · West China Hospital · NCT07106827Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HS
Phase 2 · 5 location(s) · Frantz Viral Therapeutics, LLC · NCT06075264A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT06970639Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
Phase 3 · 37 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT05692999A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · Nanjing Sanhome Pharmaceutical, Co., Ltd. · NCT07390838Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck
Phase 1 · 48 location(s) · AbbVie · NCT05005403Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrol
Phase 3 · 1 location(s) · Candel Therapeutics, Inc. · NCT07660094A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Phase 1 · 14 location(s) · Kyowa Kirin Co., Ltd. · NCT06248411A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Phase 1 · 39 location(s) · SystImmune Inc. · NCT05983432Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patie
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT04852328A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Phase 3 · 28 location(s) · Mabscale, LLC · NCT05654454A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatmen
Phase 2 · 1 location(s) · Shanghai Cancer Hospital, China · NCT06901817A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Phase 1 · 15 location(s) · Nuvectis Pharma, Inc. · NCT05873686A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 · 10 location(s) · Compass Therapeutics · NCT06150664Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/Phase 2 · 3 location(s) · GV20 Therapeutics · NCT07070518A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the B
Phase 2 · 80 location(s) · AbbVie · NCT06568939A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Ce
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07548060Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · 260 location(s) · Hoffmann-La Roche · NCT06793215Evaluation of Skin Tests in Biotherapy Allergies
NA · 1 location(s) · University Hospital, Angers · NCT06971848A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants Wit
Phase 1 · 48 location(s) · BeOne Medicines · NCT06427941A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 N
Phase 2/Phase 3 · 10 location(s) · Eikon Therapeutics · NCT07365319
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.